Thomas Sejersen

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Duchenne Muscular Dystrophy

Clinical Practice

Top Venues

Neurology. Clinical practice

Drug design, development and therapy

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Carolina Maya-González, Giorgio Tettamanti, Fulya Taylan, Anna Skarin Nordenvall, Thomas Sejersen, Ann Nordgren
Cancer Risk in Patients With Muscular Dystrophy and Myotonic Dystrophy: A Register-Based Cohort Study. Neurology 103 (8) (2024)
Mary K Schroth, Jennifer Deans, Kapil Arya, Diana Castro, Darryl C De Vivo, Melissa A Gibbons, Cristian Ionita, Nancy L Kuntz, Arpita Lakhotia, Erin Neil Knierbein, Mariacristina Scoto, Thomas Sejersen, Laurent Servais, Cuixia Tian, Megan A Waldrop, Juan Francisco Vázquez Costa
Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations. Neurology. Clinical practice 14 (4) (2024)
Mary K Schroth, Jennifer Deans, Kapil Arya, Diana Castro, Darryl C De Vivo, Melissa A Gibbons, Cristian Ionita, Nancy L Kuntz, Arpita Lakhotia, Erin Neil Knierbein, Mariacristina Scoto, Thomas Sejersen, Laurent Servais, Cuixia Tian, Megan A Waldrop, Juan Francisco Vázquez Costa
Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations. Neurology. Clinical practice 14 (4) (2024)
Erik Landfeldt, Kim Phung, Farasat Zaman, Eva Åström, Sophia Abner, Hanns Lochmüller, Thomas Sejersen, Leanne M Ward
Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence Neurology 102 (2) (2023)
Erik Landfeldt, Kim Phung, Farasat Zaman, Eva Åström, Sophia Abner, Hanns Lochmüller, Thomas Sejersen, Leanne M Ward
Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence Neurology 102 (2) (2023)
Erik Landfeldt, Kim Phung, Farasat Zaman, Eva Åström, Sophia Abner, Hanns Lochmüller, Thomas Sejersen, Leanne M Ward
Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy. Neurology 102 (2) (2023)
Erik Landfeldt, Kim Phung, Farasat Zaman, Eva Åström, Sophia Abner, Hanns Lochmüller, Thomas Sejersen, Leanne M Ward
Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy. Neurology 102 (2) (2023)
Erik Landfeldt, Kim Phung, Farasat Zaman, Eva Åström, Sophia Abner, Hanns Lochmüller, Thomas Sejersen, Leanne M Ward
Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence Neurology 102 (2) (2023)
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. Drug design, development and therapy 16 (2022)
Montse Olivé, Martin Engvall, Gianina Ravenscroft, Macarena Cabrera-Serrano, Hong Jiao, Carlo Augusto Bortolotti, Marcello Pignataro, Matteo Lambrughi, Haibo Jiang, Alistair R R Forrest, Núria Benseny-Cases, Stefan Hofbauer, Christian Obinger, Gianantonio Battistuzzi, Marzia Bellei, Marco Borsari, Giulia Di Rocco, Helena M Viola, Livia C Hool, Josep Cladera, Kristina Lagerstedt-Robinson, Fengqing Xiang, Anna Wredenberg, Francesc Miralles, Juan José Baiges, Edoardo Malfatti, Norma B Romero, Nathalie Streichenberger, Christophe Vial, Kristl G Claeys, Chiara S M Straathof, An Goris, Christoph Freyer, Martin Lammens, Guillaume Bassez, Juha Kere, Paula Clemente, Thomas Sejersen, Bjarne Udd, Noemí Vidal, Isidre Ferrer, Lars Edström, Anna Wedell, Nigel G Laing
Myoglobinopathy is an adult-onset autosomal dominant myopathy with characteristic sarcoplasmic inclusions. Nature communications 10 (1) (2019)